Market Overview

UPDATE: Piper Jaffray Upgrades Celgene Corporation to Overweight on Reduced Revlimid Reliance

Share:
Related CELG
Argus Reiterates Focus-List Buy On Celgene Following Q1 Results
Has A Biotech Recovery Started Yet?

Piper Jaffray upgraded Celgene Corporation (NASDAQ: CELG) from Neutral to Overweight and raised the price target from $86.00 to $111.00.

Piper Jaffray noted, "We are upgrading CELG to Overweight from Neutral following positive top-line data from the Apremilast Phase III psoriasis studies and new 2017 guidance that supports a 25% annual EPS growth. We expect the streak of successful clinical studies and milestones, including Apremilast (psoriatic arthritis, psoriasis), Abraxane (lung cancer approval, melanoma, pancreatic), and pomalidomide (myeloma), to translate to meaningful top-line growth, lowering CELG's reliance on Revlimid performance."

Celgene Corporation closed at $85.73 on Monday.

Latest Ratings for CELG

DateFirmActionFromTo
Apr 2016Credit SuisseMaintainsOutperform
Apr 2016BMO CapitalInitiates Coverage onOutperform
Mar 2016JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (CELG)

View Comments and Join the Discussion!